Try our Advanced Search for more refined results
Life Sciences
-
November 17, 2025
Advocacy Groups Push 9th Circ. To Uphold Fluoride Ruling
Advocacy groups that convinced a California federal judge to rule that the U.S. Environmental Protection Agency's "optimal" level for fluoride in drinking water is not protective enough for children, told the Ninth Circuit Monday that there's no reason to disturb the decision.
-
November 17, 2025
B. Braun Unit Inks $38.5M Deal To End FCA Knee Implant Case
The U.S. Department of Justice on Monday announced a $38.5 million False Claims Act settlement with a subsidiary of German medical device giant B. Braun Melsungen AG resolving accusations it sold a knee replacement implant allegedly known to fail prematurely after surgery.
-
November 17, 2025
2nd Circ. Questions Experts' Rejection In Tylenol Autism Suits
A Second Circuit panel on Monday appeared skeptical of a lower-court order that barred every expert witness set to testify for families who allege that patients taking Tylenol while pregnant can cause autism or attention deficit hyperactivity disorder in their children.
-
November 17, 2025
Medtronic Can't Nix FCA Claims Despite 1st Circ. Precedent
A Massachusetts federal judge reconsidered reviving Medtronic's bid to defeat claims it violated the False Claims Act in light of new First Circuit precedent on a causation standard, but ruled that a whistleblower's evidence warranted keeping the claims alive for now.
-
November 17, 2025
Pa. Supreme Court Snapshot: Skill Games Top Nov. Lineup
The Pennsylvania Supreme Court's November session will tackle the legality of the "Pennsylvania Skill" games that have popped up in gas stations and convenience stores, answering the long-simmering question of whether they should be regulated like slot machines. Here are some of the cases the state supreme court will hear during its three-day session in Harrisburg.
-
November 17, 2025
Cravath, Goodwin Advise On J&J's $3B Cancer Drug Play
Cravath-advised Johnson & Johnson said Monday it has agreed to pay $3.05 billion in cash for Goodwin-led Halda Therapeutics, a biotech developing a clinical-stage therapy for prostate cancer.
-
November 17, 2025
Lupin Drops Trade Secrets Case Against Rival
Pharmaceutical company Lupin Inc. has agreed to drop allegations of stealing trade secrets against Transpire Bio Inc. and former Lupin employee Xian-Ming Zeng, after two other former Lupin employees escaped the suit last month.
-
November 17, 2025
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court and Delaware Supreme Court last week had a dense slate of fiduciary duty battles, merger-process challenges, post-bankruptcy fights and a series of cases probing the limits of fraud pleading, credible-basis inspections and board-level disclosure duties.
-
November 17, 2025
3 Firms Advising On CD&R's $10.3B Bubble Wrap Maker Buy
Private equity firm CD&R has agreed to purchase Sealed Air Corp., a provider of packaging solutions including Bubble Wrap and Cryovac, at an enterprise value of $10.3 billion in a deal steered by three law firms, Sealed Air said in a Monday announcement.
-
November 17, 2025
No High Court Review For FDA Fast-Track Denial
The U.S. Supreme Court on Monday said it would not consider whether federal drug regulators went astray in denying fast-track review for a digestive disorder medication being developed by Vanda Pharmaceuticals.
-
November 14, 2025
Texas Judge Rejects Bid To Block Kenvue's $398M Dividend
Texas can't stop the makers of Tylenol from marketing the drug as safe for children and pregnant women or halt a nearly $400 million payment to shareholders, a state court ruled on Friday, rejecting arguments by Attorney General Ken Paxton's motion.
-
November 14, 2025
Amazon Blasts Claim It Destroyed Evidence In Labeling Suit
Amazon.com Services LLC is fighting calls for sanctions in a proposed class action accusing it of failing to follow federal labeling laws for dietary supplements, saying it shouldn't be penalized for allegedly failing to preserve online product pages for the supplements.
-
November 14, 2025
Apple Hit By $634M Verdict Over Masimo Health Tech Patent
A California federal jury on Friday awarded Masimo Corp. more than $634 million from Apple Inc. following an eight-day trial, finding that certain Apple Watches infringed one of Masimo's pulse oximetry patents with a feature that warns users if they have an abnormal heart rate.
-
November 14, 2025
ITC To Scrutinize Redesigned Apple Watch In Masimo IP Fight
The U.S. International Trade Commission said Friday that it would review whether redesigned Apple Watches violate a previous order that briefly blocked imports of the devices deemed to infringe a pair of patents owned by Masimo, which urged the ITC to scrutinize the modified products.
-
November 14, 2025
Ethiopian Importer Asks Court To Enforce $5M Arbitration Win
An Ethiopian import company has asked a California federal court to enforce a $5.3 million arbitral award against a medical supply company following a dispute over a botched contract.
-
November 14, 2025
Drug Buyers Defend Class Cert. In 3rd Circ. Generics Case
Direct purchasers and end-payers in the sprawling multidistrict litigation over alleged price-fixing of generic drugs are fighting requests from Actavis and Mylan to undo class certification in the cases, arguing to the Third Circuit that the litigation is a classic example of a class action matter.
-
November 14, 2025
Tricida Trustee Jackson Square Sues Over $740M Loss
The liquidating trustee for bankrupt drug developer Tricida has filed a complaint in U.S. Bankruptcy Court for the District of Delaware accusing seven former executives and directors, along with an investment firm, of systematically stripping more than $740 million in corporate assets through insider trading, self-approved bonuses and a deliberate failure to protect valuable tax attributes before its 2023 collapse.
-
November 14, 2025
DOJ Official Among Trump Picks For District Courts
President Donald Trump announced judicial nominees for federal courts in Tennessee, Indiana and Missouri on Friday, including a current U.S. Department of Justice official.
-
November 14, 2025
DC Circ. Wary Of DEA Delays In Religious Ayahuasca Case
A D.C. Circuit panel on Friday appeared skeptical that the Drug Enforcement Administration was justified in its delays processing an Iowa church's application for a religious exemption to the Controlled Substances Act to use a psychedelic in its rites.
-
November 14, 2025
Taxation With Representation: Wachtell, Paul Hastings, Sidley
In this week's Taxation With Representation, Pfizer Inc. completes its acquisition of obesity drug developer Metsera Inc., motion and controls technologies company Parker-Hannifin Corp. acquires Filtration Group Corp., and fund administrator JTC PLC backs a cash offer in the billions from British private equity shop Permira.
-
November 14, 2025
Photographer Sues Gilead For Continued Use Of Ad Images
A photographer sued Gilead Sciences Inc., claiming the pharmaceutical giant had used a set of images he'd taken for an advertisement series long after it knew its license for the photos expired.
-
November 14, 2025
Purdue's $7.4B Ch. 11 Plan To Be Confirmed
A New York bankruptcy judge agreed to confirm the $7.4 billion Chapter 11 plan of Purdue Pharma LP on Friday, saying he would issue a formal bench ruling next Tuesday explaining his decision.
-
November 14, 2025
Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy
Gibson Dunn & Crutcher LLP-advised Merck on Friday said it will broaden its respiratory portfolio with a $9.2 billion deal to buy Cooley LLP-led Cidara Therapeutics, betting that an investigational antiviral could help the company tackle the global health burden of seasonal influenza.
-
November 13, 2025
J&J Bellwether Trial Over Talc Cancer Risks Kicks Off In LA
An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a Los Angeles jury Thursday during opening statements in a bellwether trial that decades-old internal documents prove J&J knew its talc products contained toxic levels of asbestos but hid that information.
-
November 13, 2025
Hemp Policy At Crossroads After Government Reopening Bill
Hemp industry advocates are pledging to use the one-year gap between enactment and implementation of the government funding agreement, which effectively recriminalized most hemp-derived THC products, to craft new regulatory legislation that stops short of a full ban.
Expert Analysis
-
Eye Drop Ruling Clarifies Importance Of Patent Phrasing
The Federal Circuit's recent ruling in Eye Therapies v. Slayback, rejecting the Patent Trial and Appeal Board's interpretation of "consisting essentially of," highlights the importance of using clear and consistent terms throughout a patent's filing history to shield it against future challenges, says Liliana Di Nola-Baron at Panitch Schwarze.
-
How The Healthline Privacy Settlement Redefines Ad Tech Use
The Healthline settlement is the first time California has drawn a clear line in the sand around how website tracking must function in practice, so if your site uses tracking technologies, especially around sensitive content like health or finance, regulators are inspecting your website's back end, not just its banner, say attorneys at Baker Donelson.
-
How Sweeping Budget Bill Shakes Up Health Industry
With the recently passed One Big Beautiful Bill Act marking one of the most significant overhauls of federal health policy since the passage of the Affordable Care Act, providers, managed care organizations and life sciences companies must now shift focus from policy review to implementation planning, say advisers at Holland & Knight.
-
Series
Adapting To Private Practice: From ATF Director To BigLaw
As a two-time boomerang partner, returning to BigLaw after stints as a U.S. attorney and the director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, people ask me how I know when to move on, but there’s no single answer — just clearly set your priorities, says Steven Dettelbach at BakerHostetler.
-
A Look At Key 5th Circ. White Collar Rulings So Far This Year
In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.
-
High Court Cert Spotlights Varying Tests For Federal Removal
A recent decision by the U.S. Supreme Court to review Chevron v. Plaquemines Parish, a case involving the federal officer removal statute, highlights three other recent circuit court decisions raising federal removal questions, and serves as a reminder that defendants are the masters of removal actions, says Varun Aery at Hollingsworth.
-
How To Increase 3rd-Party Preissuance Patent Submissions
Attorneys Marian Underweiser and Marc Ehrlich, who helped draft the America Invents Act, discuss changes that the U.S. Patent and Trademark Office could potentially implement to facilitate its hopes for increased participation in front-end patent challenges.
-
Trump Air Emissions Carveouts Cloud The Regulatory Picture
President Donald Trump's new proclamations temporarily exempting key U.S. industries from air toxics standards, issued under a narrow, rarely-used provision of the Clean Air Act, will likely lead to legal challenges and tighter standards in some states, contributing to further regulatory uncertainty, say attorneys at GableGotwals.
-
Series
Playing Baseball Makes Me A Better Lawyer
Playing baseball in college, and now Wiffle ball in a local league, has taught me that teamwork, mental endurance and emotional intelligence are not only important to success in the sport, but also to success as a trial attorney, says Kevan Dorsey at Swift Currie.
-
What US Medicine Onshoring Means For Indian Life Sciences
Despite the Trump administration's latest moves to onshore essential medicine manufacturing, India will likely remain an indispensable component of the U.S. drug supply chain, but Indian manufacturers should prepare for stricter compliance checks, says Jashaswi Ghosh at Holon Law Partners.
-
Series
Law School's Missed Lessons: Skillful Persuasion
In many ways, law school teaches us how to argue, but when the ultimate goal is to get your client what they want, being persuasive through preparation and humility is the more likely key to success, says Michael Friedland at Friedland Cianfrani.
-
FCA Working Group Reboot Signals EHR Compliance Risk
The revival of the False Claims Act working group is an aggressive expansion of enforcement efforts by the Justice Department and the U.S. Department of Health and Human Services targeted toward technology-enabled fraud involving electronic health records and other data, say attorneys at ArentFox Schiff.
-
Litigation Inspiration: How To Respond After A Loss
Every litigator loses a case now and then, and the sting of that loss can become a medicine that strengthens or a poison that corrodes, depending on how the attorney responds, says Bennett Rawicki at Hilgers Graben.
-
While On Firmer Ground, Uncertainty Remains For SEC's ALJs
The U.S. District Court for the District of Columbia's recent opinion in Lemelson v. U.S. Securities and Exchange Commission affirmed the legitimacy of the SEC's administrative proceedings, but pointedly left unanswered the constitutional merits of tenure protection enjoyed by SEC administrative law judges — potentially the subject of future U.S. Supreme Court review, says Dean Conway at Carlton Fields.
-
FDA's Hasty Policymaking Approach Faces APA Challenges
Though the U.S. Food and Drug Administration has abandoned its usual notice-and-comment process for implementing new regulatory initiatives, two recent district court decisions make clear that these programs are still susceptible to Administrative Procedure Act challenges, says Rachel Turow at Skadden.